Levofloxacin
- Generic Name
- Levofloxacin
- Brand Names
- Levaquin, Quinsair
- Drug Type
- Small Molecule
- Chemical Formula
- C18H20FN3O4
- CAS Number
- 100986-85-4
- Unique Ingredient Identifier
- RIX4E89Y14
- Background
Levofloxacin is a fluoroquinolone antibiotic and the optical S-(-) isomer of racemic ofloxacin. It reportedly carries 8 to 128-fold more activity against both gram-negative and gram-positive bacteria compared to R-(+)-ofloxacin and remains stereochemically stable following administration (i.e. it does not invert to the inactive isomer). Levofloxacin, along w...
- Indication
In oral and intravenous formulations, levofloxacin is indicated in adults for the treatment of various infections caused by susceptible bacteria, including infections of the upper respiratory tract, lower respiratory tract, skin, skin structures, urinary tract, and prostate. The oral formulation is also indicated in both adults and children 6 months of age a...
- Associated Conditions
- Abscesses caused by susceptible bacteria, Acute Bacterial Exacerbation of Chronic Bronchitis (ABECB) caused by susceptible bacteria, Acute Pyelonephritis caused by Infection Due to Escherichia Coli, Bacterial Conjunctivitis caused by susceptible bacteria, Cellulitis caused by susceptible bacteria, Community Acquired Pneumonia (CAP) caused by susceptible bacteria, Furuncle caused by susceptible bacteria, Impetigo caused by susceptible bacteria, Inhalational Anthrax, Nosocomial Pneumonia caused by Pseudomonas Infections, Nosocomial Pneumonia caused by susceptible bacteria, Plague caused by Yersinia pestis, Pyoderma caused by susceptible bacteria, Wound Infections caused by susceptible bacteria, Acute bacterial sinusitis caused by susceptible bacteria, Chronic Bacterial prostatitis caused by susceptible bacteria, Chronic Pseudomonas Infections, Complicated Urinary Tract Infection caused by susceptible bacteria, Complicated skin and skin-structure infections caused by susceptible bacteria, Uncomplicated Urinary Tract Infection caused by susceptible bacteria, Uncomplicated skin and skin-structure infections caused by susceptible bacteria
- Associated Therapies
- -
A Study to Evaluate the Pharmacokinetics and Safety of Levofloxacin in Patients With Varying Degrees of Renal Function.
- Conditions
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2011-06-08
- Target Recruit Count
- 59
- Registration Number
- NCT00645437
Study of the Safety and Efficacy of Cefdinir and Levofloxacin for the Treatment of Subjects With Acute Bacterial Sinusitis
- Conditions
- Interventions
- First Posted Date
- 2008-03-27
- Last Posted Date
- 2008-03-27
- Lead Sponsor
- Abbott
- Target Recruit Count
- 271
- Registration Number
- NCT00645073
A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Sinus Infections in Adults
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2011-05-11
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 541
- Registration Number
- NCT00643409
- Locations
Pfizer Investigational Site
A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Acute Symptoms of Chronic Bronchitis
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2011-05-16
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 551
- Registration Number
- NCT00644449
- Locations
- 🇻🇪
Pfizer Investigational Site, Caracas, Venezuela
A Multicenter, Randomized, Double-Blind, Double-Dummy Trial of Azithromycin SR Compared With Levofloxacin for the Treatment of Mild to Moderate Pneumonia in Adult Patients
- Conditions
- Interventions
- First Posted Date
- 2008-03-26
- Last Posted Date
- 2008-03-26
- Lead Sponsor
- Pfizer
- Target Recruit Count
- 468
- Registration Number
- NCT00643734
- Locations
- 🇷🇺
Pfizer Investigational Site, Smolensk, Russian Federation
Safety and Efficacy of an Antibiotic Sponge in Diabetic Patients With a Mild Infection of a Foot Ulcer
- Conditions
- Interventions
- First Posted Date
- 2008-01-15
- Last Posted Date
- 2022-05-31
- Lead Sponsor
- Innocoll
- Target Recruit Count
- 70
- Registration Number
- NCT00593567
- Locations
- 🇺🇸
Chesapeake Research Group LLC, Pasadena, Maryland, United States
MDR TB, Levofloxacin, Multi-Drug-Resistant Pulmonary Tuberculosis
- First Posted Date
- 2007-07-03
- Last Posted Date
- 2009-03-04
- Lead Sponsor
- Sanofi
- Target Recruit Count
- 100
- Registration Number
- NCT00495339
- Locations
- 🇷🇺
Sanofi-Aventis, Moscow, Russian Federation
Ceftriaxone Vs Levofloxacin on Cytokine Expression in Pneumococcal Pneumonia
- Conditions
- First Posted Date
- 2007-02-01
- Last Posted Date
- 2007-02-01
- Lead Sponsor
- Hospital Mutua de Terrassa
- Target Recruit Count
- 45
- Registration Number
- NCT00429975
- Locations
- 🇪🇸
Hospital Mutua de Terrassa, Terrassa, Barcelona, Spain
An Effectiveness and Safety Study for Levofloxacin in Chronic Prostatitis
- First Posted Date
- 2006-11-22
- Last Posted Date
- 2013-09-13
- Target Recruit Count
- 242
- Registration Number
- NCT00402688
Early Bactericidal Activity of Linezolid, Gatifloxacin, Levofloxacin, Isoniazid (INH) and Moxifloxacin in HIV Negative Adults With Initial Episodes of Sputum Smear-Positive Pulmonary Tuberculosis
- Conditions
- Interventions
- First Posted Date
- 2006-11-06
- Last Posted Date
- 2018-11-08
- Target Recruit Count
- 70
- Registration Number
- NCT00396084
- Locations
- 🇺🇸
San Francisco General Hospital - Pulmonary and Critical Care Medicine, San Francisco, California, United States
🇧🇷Universidade Federal do Espirito Santo - Duke Hubert-Yeargan Center, Vitória, Espírito Santo, Brazil
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.